The nerve switch Sironax wants to keep switched off
SIR2501, a SARM1 blocker with FDA Fast Track status for chemo nerve damage, gets three poster slots in Washington. Sironax’s lead drug is turning up in an odd mix of places this month: ALS, chemotherapy-related nerve damage, glaucoma and stroke. The Waltham, Massachusetts biotech has three abstracts
<p>SIR2501, a SARM1 blocker with FDA Fast Track status for chemo nerve damage, gets three poster slots in Washington. Sironax’s lead drug is turning up in an odd mix of places this month: ALS, chemotherapy-related nerve damage, glaucoma and stroke. The Waltham, Massachusetts biotech has three abstracts</p>